Details for Patent: 8,759,388

Title:	Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Abstract:	Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
Inventor(s):	deLong; Mitchell A. (Chapel Hill, NC), Sturdivant; Jill Marie (Chapel Hill, NC), Royalty; Susan M. (Davis, CA)
Assignee:	Aerie Pharmaceuticals, Inc. (Research Triangle Park, NC)
Filing Date:	Apr 09, 2012
Application Number:	13/442,263
Claims:	1. A compound of formula (III): ##STR00063## or any optical isomer, diastereomer, enantiomer, tautomer, or physiologically acceptable salt thereof; wherein R.sub.1 and R.sub.2 are, independently, hydrogen, C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.1-C.sub.4 carbonyl, C.sub.1-C.sub.4 carbonylamino, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 sulfonyl, C.sub.1-C.sub.4 sulfonylamino, C.sub.1-C.sub.4 thioalkyl or C.sub.1-C.sub.4 carboxyl; or R.sub.1 and R.sub.2 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms, or R.sub.1 and R.sub.3 combine to form a heterocycloalkyl ring of at least 5 and at most 8 member atoms; wherein R.sub.4 is hydrogen, unsubstituted C.sub.1-4 alkyl or phenyl; wherein, one of the R.sub.3 groups is an aryl group, a heteroaryl group, a cycloalkyl group, or a heterocycloalkyl group, and the other R.sub.3 groups are, independently, hydrogen or C.sub.1-C.sub.4 alkyl; wherein n is 1 to 4; and wherein, X.sub.1 and X.sub.2 are, independently, hydrogen, hydroxyl, halogen, C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 alkynyl, amino, nitro, cyano, C.sub.1-C.sub.4 carbonyl, C.sub.1-C.sub.4 carbonylamino, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 sulfonyl, C.sub.1-C.sub.4 sulfonylamino, C.sub.1-C.sub.4 thioalkyl or C.sub.1-C.sub.4 carboxyl. 2. The compound according to claim 1, wherein n is 1 to 3. 3. The compound according to claim 2, wherein n is 2. 4. The compound according to claim 1, wherein one R.sub.3 is aryl, or heteroaryl. 5. The compound according to claim 1, wherein X.sub.1 and X.sub.2 are, independently, hydrogen or chloro or fluoro. 6. The compound according to claim 1, wherein R.sub.4 is hydrogen. 7. The compound according to claim 1, wherein n is 2; wherein one R.sub.3 is aryl or heteroaryl; wherein X.sub.1 and X.sub.2 are, independently, hydrogen, chloro or fluoro; and wherein R.sub.4 is hydrogen. 8. The compound according to claim 7, wherein the other R.sub.3 groups are hydrogen. 9. The compound according to claim 4, wherein one R.sub.3 is thienyl. 10. The compound according to claim 4, wherein one R.sub.3 is monosubstituted phenyl or monosubstituted thienyl. 11. The compound according to claim 10, wherein the substituent is fluoro, chloro, or cyano. 12. The compound according to claim 4, wherein one R.sub.3 is unsubstituted phenyl or unsubstituted thienyl. 13. The compound according to claim 1, wherein X.sub.1 and X.sub.2 are hydrogen. 14. The compound according to claim 1 having a formula of: TABLE-US-00014 ##STR00064## R1 R2 H H Cl H Cl CH.sub.3 H C.sub.6H.sub.5 H CH.sub.3 or the formula: TABLE-US-00015 ##STR00065## R6 R5 R4 R3 R2 R1 H H H (S)-C.sub.6H.sub.5 H H H H C.sub.6H.sub.5 H H H. 15. The compound according to claim 1, wherein n is 2; R.sub.1 and R.sub.2 are, independently, hydrogen or methyl; one R.sub.3 is 3-thienyl or 2-thienyl; the other R.sub.3 are hydrogen; R.sub.4 is hydrogen; and X.sub.1 and X.sub.2 are hydrogen. 16. A composition comprising a compound according to claim 1 and a carrier. 17. The composition of claim 16, wherein the carrier is saline buffered to a pH of about 5.5 to about 6.5.